(Q40821360)

24 September 2017

1 reference

title

Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy (English)

1 reference

24 September 2017

1 reference

1 reference

Spitalewitz S

1

1 reference

24 September 2017

Porush JG

series ordinal

2

1 reference

24 September 2017

Cattran D

series ordinal

3

1 reference

24 September 2017

Wright N

series ordinal

4

1 reference

24 September 2017

publication date

1 July 1993

1 reference

American Journal of Kidney Diseases

24 September 2017

published in

1 reference

24 September 2017

volume

22

1 reference

24 September 2017

issue

1

1 reference

24 September 2017

page(s)

143-150

1 reference

The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Management of hyperlipidemia of kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

The Nephrotic Syndrome and Ischaemic Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Does the nephrotic syndrome increase the risk of cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Cardiovascular Disease and the Nephrotic Syndrome: the other Side of the Coin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Ischaemic heart-disease as a complication of nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Fibric acids: effects on lipids and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Treatment of nephrotic hyperlipoproteinemia with gemfibrozil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Probucol inhibits oxidative modification of low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Effect of probucol on hyperlipidemia in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2970180-4

7 January 2021

10.1016/S0272-6386(12)70180-4

Identifiers

DOI

1 reference

release_vczyswanpjcrtm7kpxmgqs5weu

24 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vczyswanpjcrtm7kpxmgqs5weu

24 November 2022

mapped directly with Wikidata item

1 reference